<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619783</url>
  </required_header>
  <id_info>
    <org_study_id>A35-011</org_study_id>
    <nct_id>NCT05619783</nct_id>
  </id_info>
  <brief_title>Extension Study Evaluating The Safety And Tolerability of AMX0035</brief_title>
  <official_title>A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants With Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amylyx Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amylyx Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the safety and tolerability of AMX0035 over 108 weeks of&#xD;
      open label treatment for participants previously enrolled in Study A35-004 (PHOENIX).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will receive open-label treatment with AMX0035, starting on Day 1 with twice&#xD;
      a day oral dosing (once in the morning and once in the evening) for the duration of the&#xD;
      study. After the Baseline Visit (Day 1), enrolled participants will complete visits&#xD;
      approximately every 12 weeks (Â± 2 weeks), until Week 108 or the end of treatment (EOT) visit,&#xD;
      followed by a safety follow-up approximately 28 days after the last dose. A survival&#xD;
      follow-up assessment will be completed every 12 weeks following the EOT visit until time of&#xD;
      death or end of study (EOS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 29, 2022</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the Incidence of Treatment-Emergent Adverse Events during treatment with AMX0035</measure>
    <time_frame>108 weeks</time_frame>
    <description>Incidence of all adverse events (AE)s; AEs leading to treatment discontinuation or study withdrawal, and all serious adverse events (SAE)s in participants treated with AMX0035</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of long-term treatment with AMX0035 on survival</measure>
    <time_frame>108 weeks</time_frame>
    <description>Overall survival of all-cause mortality&#xD;
Ventilation free survival (defined as death, tracheostomy for respiratory distress or permanent non-invasive ventilation [&gt;22 hours per day for 7 consecutive days])</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will be treated with oral (or feeding tube) AMX0035 (a fixed-dose combination of Sodium Phenylbutyrate (PB) and taurursodiol). All participants will take 2 sachets daily (one morning dose and one evening dose) starting on Day 1, for the duration of the study (if twice a day dosing is poorly tolerated, dosing interruptions and reductions are further discussed in section 6.3) AMX0035 will be supplied by Amylyx as a carton box containing approximately 1 month supply of single use sachets. Each AMX0035 sachet contains active ingredients in a powder formulation with 3 g PB and 1 g taurursodiol. AMX0035 powder is mixed with water and taken orally (or via feeding tube).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMX0035</intervention_name>
    <description>Combination of 3 g phenylbutyrate and 1 g taurursodiol</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>RELYVRIO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Previous participation in Study A35-004 (PHOENIX), including completion of the&#xD;
             randomized controlled phase through Week 48 (this timepoint may be upcoming at the&#xD;
             time of screening). Participants who do not complete randomized-controlled phase&#xD;
             through Week 48 for medical reasons may be included on a case-by-case basis, in&#xD;
             consultation with the Sponsor;&#xD;
&#xD;
          2. Capable of providing informed consent;&#xD;
&#xD;
          3. Capable and willing to follow trial procedures including visits to the trial clinic,&#xD;
             remote visits, and survival status reporting requirements;&#xD;
&#xD;
          4. Women of childbearing potential (WOCBP; e.g., not post-menopausal for at least one&#xD;
             year or surgically sterile must agree to use adequate birth control for the duration&#xD;
             of the trial and 3 months after the last dose of AMX0035;&#xD;
&#xD;
               1. 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with&#xD;
                  serum Follicle-stimulating hormone (FSH) levels &gt; 40 mIU/ml (milli-international&#xD;
                  units per milliliter) or 6 weeks postsurgical bilateral oophorectomy with or&#xD;
                  without hysterectomy.&#xD;
&#xD;
               2. Acceptable contraception methods for use in this trial are:&#xD;
&#xD;
                    -  Hormonal methods, such as birth control pills, patches, injections, vaginal&#xD;
                       ring, or implants;&#xD;
&#xD;
                    -  Barrier methods (such as a condom or diaphragm) used with a spermicide (a&#xD;
                       foam, cream, or gel that kills sperm);&#xD;
&#xD;
                    -  Intrauterine device (IUD);&#xD;
&#xD;
                    -  Abstinence (no heterosexual sex);&#xD;
&#xD;
                    -  Unique partner who is surgically sterile (men) or not of childbearing&#xD;
                       potential (female).&#xD;
&#xD;
          5. Women must not be pregnant or planning to become pregnant for the duration of the&#xD;
             trial and 3 months after last dose of AMX0035;&#xD;
&#xD;
          6. Men must agree to practice contraception for the duration of the trial and for at&#xD;
             least 3 months after last dose of AMX0035;&#xD;
&#xD;
          7. Men must not plan to father a child or to provide sperm for donation for the duration&#xD;
             of the trial and 3 months after the last dose of AMX0035&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of known allergy to phenyl butyrate or bile salts;&#xD;
&#xD;
          2. Abnormal liver function defined as bilirubin levels and/or aspartate aminotransferase&#xD;
             (AST) and/or alanine aminotransferase (ALT) &gt; 5 times the upper limit of the normal&#xD;
             (obtained within 12 weeks from first dose);&#xD;
&#xD;
          3. Renal insufficiency as defined by estimated glomerular filtration rate (eGFR) &lt;60&#xD;
             mL/min/1.73m2 normal (obtained within 12 weeks from first dose);&#xD;
&#xD;
          4. Pregnant women or women currently breastfeeding;&#xD;
&#xD;
          5. Current severe biliary disease which may result in the Investigator medical judgement&#xD;
             in biliary obstruction including for example active cholecystitis, primary biliary&#xD;
             cirrhosis, sclerosing cholangitis, gallbladder cancer, gangrene of the gallbladder,&#xD;
             abscess of the gallbladder;&#xD;
&#xD;
          6. History of Class III/IV heart failure (per New York Heart Association - NYHA);&#xD;
&#xD;
          7. Participant under severe salt restriction where the added salt intake due to treatment&#xD;
             would put the participant at risk, in the Investigator clinical judgment;&#xD;
&#xD;
          8. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance&#xD;
             abuse that would impair ability of the participant to provide informed consent,&#xD;
             according to Investigator judgment;&#xD;
&#xD;
          9. Clinically significant unstable medical condition (other than ALS) (e.g.,&#xD;
             cardiovascular instability, systemic infection, untreated thyroid dysfunction, severe&#xD;
             laboratory test anomaly or clinically significant electrocardiogram [ECG] changes)&#xD;
             that would pose a risk to the participant if he/she were to participate in the trial,&#xD;
             according to Investigator judgment;&#xD;
&#xD;
         10. Currently enrolled in another trial (excluding Study A35-004 (PHOENIX)) involving use&#xD;
             of an investigational therapy (or within 5 plasma half-lives) prior to first dose at&#xD;
             Baseline Visit;&#xD;
&#xD;
         11. Implantation of Diaphragm Pacing System (DPS);&#xD;
&#xD;
         12. Currently or previously treated within the last 30 days (or 5 half-lives, whichever is&#xD;
             longer) from first dose at the Baseline Visit or planned exposure during the treatment&#xD;
             period to any prohibited medications listed in Section 6.7 of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lahar Mehta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Head, Global Clinical Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon HÃ´pital Neurologique Pierre Wertheimer Cellule MutualisÃ©e de Recherche Clinique (CMRC)</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied Service de Neurologie</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - HÃ´pital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - HÃ´pital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pitaux Universitaires de Marseille Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gui de Chauliac</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital de la SalpÃªtriÃ¨re</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le Centre Hospitalier RÃ©gional Universitaire de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jena University Hospital</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische FakultÃ¤t Mannheim der UniversitÃ¤t Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulm University Medical Centre</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity College Dublin/Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Auxologico italiano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico NEMO</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS - Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Milan Medical School</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  degli Studi della Campania Luigi Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padua</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Torino</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Linden</name>
      <address>
        <city>KrakÃ³w</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinic Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar UniversitÃ¡rio Lisboa-Norte</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge-IDIBELL</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Basurto</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Rafael</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biodonostia Health Research Institute; Hospital Universitario Donostia</name>
      <address>
        <city>San SebastiÃ¡n</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y PolitÃ©cnico La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UmeÃ¥ University Hospital</name>
      <address>
        <city>UmeÃ¥</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Walton Centre NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Queen Square Institute of Neurology</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Plymouth</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital Barnes Clinical Research Team</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Institute for Translational Neuroscience (SITraN)</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>October 27, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>May 5, 2023</last_update_submitted>
  <last_update_submitted_qc>May 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

